Canadians with a chronic illness face costs of between a few hundred dollars to over a $1,000 per yea By Danielle Martin and Steve Morgan : Decision makers often talk of “low hanging fruit” – policies that involve minimal disruption but can yield quick wins. Pharmacare – a program that would see all prescription drug [...]
Health Canada’s slower approval process potentially harms patients who otherwise might be able to buy the new drugs. Thus, the federal government could speed up access by harmonizing with the Europeans and Americans on regulatory approvals. It would save companies and taxpayers money and help those in need of the newer drugs.